China SXT Pharmaceuticals, Inc. — Form 6-K
Filing date: October 8, 2026. The filing reports a correction to the warrant exercise price in a press release about a registered direct offering.
Offering and correction
- The offering consists of units, each comprising one Class A ordinary share or a pre-funded warrant in lieu of a share, and one common warrant.
- The corrected initial exercise price of the common warrants is $2.75 per Class A ordinary share. The filing says the earlier press release contained a typographical error.
- The revised press release is identified as Exhibit 99.1, but its full text and further offering terms are not included in the supplied filing text.
Financial information and outlook
This 6-K provides no revenue, profit, cash flow, margin, debt, liquidity, or comparative-period figures. It also provides no guidance, business outlook, or discussion of contingencies.
Key facts to verify
- Review Exhibit 99.1 and the offering documents for the number and price of units, gross proceeds, fees, and other terms.
- Confirm the final warrant terms, including the $2.75 initial exercise price and any adjustments or expiration provisions.
- Check subsequent filings for closing status, proceeds received, and potential dilution from shares and warrants issued.